In vivo production of pederin by labrenzin pathway expansion

IF 3.7 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Metabolic Engineering Communications Pub Date : 2022-06-01 DOI:10.1016/j.mec.2022.e00198

Dina Kačar , Carmen Schleissner , Librada M. Cañedo , Pilar Rodríguez , Fernando de la Calle , Carmen Cuevas , Beatriz Galán , José Luis García

{"title":"In vivo production of pederin by labrenzin pathway expansion","authors":"Dina Kačar , Carmen Schleissner , Librada M. Cañedo , Pilar Rodríguez , Fernando de la Calle , Carmen Cuevas , Beatriz Galán , José Luis García","doi":"10.1016/j.mec.2022.e00198","DOIUrl":null,"url":null,"abstract":"<div>Pederin is a potent polyketide toxin that causes severe skin lesions in humans after contact with insects of genus Paederus. Due to its potent anticancer activities, pederin family compounds have raised the interest of pharmaceutical industry. Despite the extensive studies on the cluster of biosynthetic genes responsible for the production of pederin, it has not yet been possible to isolate and cultivate its bacterial endosymbiont producer. However, the marine bacterium Labrenzia sp. PHM005 was recently reported to produce labrenzin, the closest pederin analog. By cloning a synthetic pedO gene encoding one of the three O-methyltraferase of the pederin cluster into Labrenzia sp. PHM005 we have been able to produce pederin for the first time by fermentation in the new recombinant strain.</div>","PeriodicalId":18695,"journal":{"name":"Metabolic Engineering Communications","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214030122000074/pdfft?md5=5dd8f3cd4cbadeb5d281286c91f9e536&pid=1-s2.0-S2214030122000074-main.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Metabolic Engineering Communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2214030122000074","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Pederin is a potent polyketide toxin that causes severe skin lesions in humans after contact with insects of genus Paederus. Due to its potent anticancer activities, pederin family compounds have raised the interest of pharmaceutical industry. Despite the extensive studies on the cluster of biosynthetic genes responsible for the production of pederin, it has not yet been possible to isolate and cultivate its bacterial endosymbiont producer. However, the marine bacterium Labrenzia sp. PHM005 was recently reported to produce labrenzin, the closest pederin analog. By cloning a synthetic pedO gene encoding one of the three O-methyltraferase of the pederin cluster into Labrenzia sp. PHM005 we have been able to produce pederin for the first time by fermentation in the new recombinant strain.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

labrenzin通路扩张在体内产生pederin

Pederin是一种强效的聚酮毒素，在与pepederus属昆虫接触后会引起严重的皮肤损伤。由于其强大的抗癌活性，菊酯类化合物已引起了医药行业的广泛关注。尽管对产生pederin的生物合成基因簇进行了广泛的研究，但尚未能够分离和培养其细菌内共生生产者。然而，海洋细菌Labrenzia sp. PHM005最近被报道产生labrenzin，这是最接近的同性恋类似物。通过将一个合成的pedO基因克隆到Labrenzia sp. PHM005中，首次在重组菌株中发酵生产了pederin。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Metabolic Engineering Communications Medicine-Endocrinology, Diabetes and Metabolism

CiteScore

13.30

自引率

1.90%

发文量

审稿时长

18 weeks

期刊介绍： Metabolic Engineering Communications, a companion title to Metabolic Engineering (MBE), is devoted to publishing original research in the areas of metabolic engineering, synthetic biology, computational biology and systems biology for problems related to metabolism and the engineering of metabolism for the production of fuels, chemicals, and pharmaceuticals. The journal will carry articles on the design, construction, and analysis of biological systems ranging from pathway components to biological complexes and genomes (including genomic, analytical and bioinformatics methods) in suitable host cells to allow them to produce novel compounds of industrial and medical interest. Demonstrations of regulatory designs and synthetic circuits that alter the performance of biochemical pathways and cellular processes will also be presented. Metabolic Engineering Communications complements MBE by publishing articles that are either shorter than those published in the full journal, or which describe key elements of larger metabolic engineering efforts.